BioInvent International Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de BioInvent International de 89% y 55.8% respectivamente, mientras que el BPA crecerá en un 139.8% al año.

Información clave

102.7%

Tasa de crecimiento de los beneficios

166.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	46.4%
Tasa de crecimiento de los ingresos	77.3%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	27 Sep 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?

Aug 16

We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

Apr 09

Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

Sep 01

Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive

Jun 02

Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week

Feb 25

We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Sep 28

Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook

Aug 31

Previsiones de crecimiento de beneficios e ingresos

OM:BINV - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	606	261	N/A	263	1
12/31/2025	647	446	N/A	155	1
12/31/2024	64	-354	N/A	-419	1
6/30/2024	53	-383	-376	-364	N/A
3/31/2024	61	-335	-341	-329	N/A
12/31/2023	71	-330	-355	-342	N/A
9/30/2023	77	-311	-358	-341	N/A
6/30/2023	68	-304	-77	-62	N/A
3/31/2023	326	-48	-53	-40	N/A
12/31/2022	326	-43	-54	-41	N/A
9/30/2022	310	-43	-54	-45	N/A
6/30/2022	295	-42	-289	-276	N/A
3/31/2022	30	-266	-290	-276	N/A
12/31/2021	19	-278	-259	-246	N/A
9/30/2021	113	-171	-153	-141	N/A
6/30/2021	126	-141	-123	-115	N/A
3/31/2021	137	-123	-85	-78	N/A
12/31/2020	147	-76	-69	-63	N/A
9/30/2020	74	-146	-125	-119	N/A
6/30/2020	76	-150	-117	-112	N/A
3/31/2020	93	-144	-124	-120	N/A
12/31/2019	94	-139	-129	-125	N/A
9/30/2019	79	-130	-139	-136	N/A
6/30/2019	68	-116	-152	-148	N/A
3/31/2019	45	-126	-156	-152	N/A
12/31/2018	39	-123	-145	-141	N/A
9/30/2018	42	-124	-136	-126	N/A
6/30/2018	42	-123	-128	-116	N/A
3/31/2018	43	-103	N/A	-99	N/A
12/31/2017	45	-101	N/A	-76	N/A
9/30/2017	62	-75	N/A	-76	N/A
6/30/2017	56	-82	N/A	-75	N/A
3/31/2017	55	-85	N/A	-81	N/A
12/31/2016	71	-63	N/A	-72	N/A
9/30/2016	50	-76	N/A	-59	N/A
6/30/2016	51	-70	N/A	-46	N/A
3/31/2016	45	-69	N/A	-50	N/A
12/31/2015	16	-91	N/A	-73	N/A
9/30/2015	8	-98	N/A	-87	N/A
6/30/2015	17	-86	N/A	-79	N/A
3/31/2015	46	-57	N/A	-73	N/A
12/31/2014	47	-54	N/A	-76	N/A
9/30/2014	95	-5	N/A	-27	N/A
6/30/2014	92	-10	N/A	-42	N/A
3/31/2014	72	-23	N/A	-55	N/A
12/31/2013	82	-18	N/A	-55	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BINV sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1%).

Beneficios vs. Mercado: Se prevé que BINV sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que BINV sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (55.8% al año) de BINV crezcan más rápidamente que los del mercado Swedish (1.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (55.8% al año) de BINV crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BINV se prevé que sea elevada dentro de 3 años.

BioInvent International Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 23% to kr83.00

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Price target increased to kr113

Forecast to breakeven in 2024

Recent updates

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma

Bioinvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program

Second quarter 2024 earnings released: kr2.09 loss per share (vs kr1.34 loss in 2Q 2023)

Is BioInvent International (STO:BINV) In A Good Position To Invest In Growth?

BioInvent Receives Notice of Allowance from USPTO for BI-1910 Patent Application

Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024

BioInvent International Gains Patent for BI-1808 in China

BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024

Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL

First quarter 2024 earnings released: kr1.18 loss per share (vs kr1.12 loss in 1Q 2023)

Price target decreased by 23% to kr83.00

We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

BioInvent International AB (publ) to Report Nine Months, 2024 Results on Oct 31, 2024

BioInvent International AB (publ), Annual General Meeting, May 03, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioInvent International AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2024

New minor risk - Market cap size

BioInvent International AB (publ) Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607

Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910

BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent

BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors

Independent Director recently bought kr603k worth of stock

Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Market cap size

Independent Director recently bought kr238k worth of stock

BioInvent International AB (publ) Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies

BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023

BioInvent International AB Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent Ready for Combination Studies with BT-001

Independent Chairman of the Board recently bought kr127k worth of stock

Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive

Independent Chairman of the Board recently bought kr127k worth of stock

BioInvent International AB (Publ) Appoints of Ingunn Munch Lindvig as Senior Vice President Regulatory Affairs

High number of new directors

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analyst expectations

Forecast to breakeven in 2025

Full year 2022 earnings released: kr0.69 loss per share (vs kr5.14 loss in FY 2021)

Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week

Forecast to breakeven in 2025

BioInvent International AB (publ), Annual General Meeting, Apr 27, 2023

Bioinvent International AB Provides Update on Its Clinical and Pre-Clinical Pipeline, Including an Update on Its Lead Drug Candidate, the Novel Anti-Fc?RIIB Antibody Bi-1206

BioInvent International AB (publ) Receives FDA IND Approval for Anti-FcyRIIB Antibody BI-1607

Price target increased to kr113

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Consensus revenue estimates increase by 130%

Price target increased to kr112

BioInvent International AB (publ) Completes Dose Escalation Part of the Phase I/IIa Study with Anti-TNFR2 Drug Candidate BI-1808

CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China

BioInvent International AB (publ) to Report Q2, 2023 Results on Aug 30, 2023

BioInvent International AB (publ) to Report Q1, 2023 Results on Apr 26, 2023

Consensus forecasts updated

Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook

Price target increased to kr115

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioInvent International AB (publ) Enrolls First Patient in Phase 1/2A Trial of Bi-1607 in HER2 Positive Solid Tumors

Bioinvent International Resolves to Elect Natalie Berner and Nanna Lüneborg as New Board Members

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Bioinvent International AB (Publ) Appoints Sylvie Ryckebusch as Chief Business Officer

Forecast to breakeven in 2023

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind